The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPURE.L Regulatory News (PURE)

  • There is currently no data for PURE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

5 Jan 2017 07:00

RNS Number : 4103T
PureCircle Limited
05 January 2017
 

 

 

5th January 2017

PureCircle Limited

Trading Update

 

PureCircle (LSE: PURE), the world's leading producer and marketer of high purity stevia ingredients, today provides a trading update for the six-month period ended 31 December 2016 (H1 FY17).

PureCircle's mission is to lead the global expansion of stevia as the next mass volume, natural sweetener and thus to encourage healthier diets around the world.

 

Financial Performance

Sales

The Group has achieved very strong growth in Europe and Latin America, which together represent over half of its sales. Globally, in the last six months, there have been over 100 launches that contain PureCircle products, an increase on the prior year. This is a clear indication that the demand for stevia based products is increasing and that, on an underlying basis, our business is in growth.

Group sales in H1 FY17 are expected to be $47m, a decrease of 14% against H1 FY16 (US$54m). This decrease is a direct consequence of the previously announced detainment of shipments by US Customs Border Protection ('CBP') partially offset by strong growth in the rest of the world.

 

Margins, EBITDA and Net Profit

The Group expects gross margin, EBITDA and net profit to be lower compared to H1 FY16 due to the aforementioned US CBP detainment order. The cost of this weighed on our margins in H1, though we expect margins to be restored to previous levels once the issue has been resolved.

Group gross profit for the first half is expected to be US$18m, a decline of 19% against H1 FY16 (US$22m) and EBITDA is expected to be US$8m, a decrease of $5m, reflecting the lower sales and adverse margins.

 

The Group's net loss is expected to be US$2m (1H FY16 profit: US$5m).

 

Cash, Net Debt and Funding Headroom

Following the planned capital expenditure for the capacity expansion of the company's refinery facility in Kuala Lumpur, the Group ended H1 FY17 with net debt of US$80m (H1 FY16 US$46m). The Group has cash and facility headroom of US$75m (H1 FY16 US$73m).

 

The company's interim results will be announced on Tuesday 7 March 2017.

 

US Customs Border Protection ("US CBP") Update

The company has worked extensively with the US CBP, providing tracking documents and related data in response to their detailed requests. We are now awaiting a decision from the CBP.

The impoundment of our shipments and the inclusion of PureCircle's name on the Withhold Release Order ("WRO") has inevitably had a significant negative impact on our market in the US, hence adversely impacting our H1 results. The US market constitutes one third of our sales.

We anticipate a further communication to the market in the near term.

 

Commenting on the H1 FY17 trading update, the Group CEO Magomet Malsagov said: 

"H1 FY17 has seen continued positive market sentiment for stevia with an ever increasing array of products being launched in the food and beverage categories. These launches are not just confined to the traditional mature markets of North America and Western Europe. I am particularly excited to see our expansion in Latin America and South Asia with a new office being opened in India.

The macro market trends continue to develop in our favour with increasing global obesity and diabetes trends well documented. The implementation of sugar taxes in various countries has also added to the momentum of our industry.

Whilst the US CBP process has been a major distraction for our business in H1 FY17 and has adversely impacted our sales growth in the United States, I am delighted by the continued growth in sales in the rest of the world, which has further diversified our sales footprint, and by the strong customer support that we continue to receive. We have progressed our R&D and leaf development programmes by conducting large scale field trials of new leaf varieties with high content of better tasting novel natural sweeteners Reb M and Reb D. These new leaf plantations are planned to be scaled to thousands of hectares beginning in 2017. Our new state of the art, fully automated refinery, encapsulating all the latest technology developments is complete and will be commissioned in the first quarter of CY2017. With these positive dynamics, and an anticipated resolution to the US CBP issue in the near future, I am confident in our mid to long term prospects and look forward to returning to our growth trajectory."

 

Enquiries:

 

 

 

 

PureCircle Limited

www.purecircle.com

Magomet Malsagov, CEO

Via Redleaf

Rakesh Sinha, CFO

 

 

 

Redleaf Communications

purecircle@redleafpr.com

Emma Kane

+44 20 7382 4747

Rebecca Sanders-Hewett

 

David Ison

 

 

 

 

 

Notes to Editors

PureCircle is the world's leading producer of high-purity stevia ingredients for the global food and beverage industry. Its mission is to encourage healthier diets around the world through the supply of natural ingredients to the global food and beverage industry. Its vision is to lead the global expansion of stevia as the next mass volume, natural-origin sweetener. PureCircle has offices around the world with the global headquarters in Kuala Lumpur, Malaysia. The Business was founded in 2002. PureCircle's shares are listed on the main market of the London Stock Exchange and trade under the ticker symbol PURE. For more information, visit: www.purecircle.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTOKPDQABKKFDK
Date   Source Headline
29th Oct 20097:00 amRNSProduct Launch
27th Oct 200912:35 pmRNSHolding(s) in Company
21st Oct 20097:00 amRNSPureCircle and PepsiCo to receive Scientific Excel
20th Oct 20097:00 amRNSProduct Launch
15th Oct 200910:00 amRNSTrading Statement
8th Oct 20097:00 amRNSDirector Declaration
23rd Sep 20097:00 amRNSFinal Results
8th Sep 20098:32 amRNSStatement re Approval
4th Sep 20093:00 pmRNSStatement re Shareholding
2nd Sep 200910:10 amRNSChange of Adviser
8th Jul 20097:00 amRNSTrading Update
15th Jun 20098:41 amRNSNotification of a Major Interest
27th Apr 20097:02 amRNSCompletion of Extract Plant Complex
1st Apr 20097:00 amRNSDealings in Shares
5th Mar 20099:20 amRNSDirector's Dealing
4th Mar 20097:00 amRNSHalf Yearly Report
29th Jan 20097:00 amRNSSENIOR INTERNATIONAL SALES TEAM APPOINTMENT
19th Jan 20097:00 amRNSAppointment
13th Jan 20097:00 amRNSAppointment of Head of PureCircle USA
12th Jan 20097:09 amRNSNotice of Results
6th Jan 20097:00 amRNSStrategic Global Collaboration
5th Jan 20097:00 amRNSDirector Dealings
18th Dec 20087:00 amRNSRegulatory Approval
24th Nov 20087:51 amRNSExecutive Management Appointments
10th Nov 20087:55 amRNSIssuance of Options
7th Nov 20089:51 amRNSExercise of Options
17th Oct 20083:05 pmRNSDealings in shares
15th Oct 20087:00 amRNSFinal Results
13th Oct 200812:58 pmRNSBoard Change
10th Oct 20089:44 amRNSApproval Announced
22nd Aug 20087:00 amRNSRevised Results Day
20th Aug 20088:42 amRNSBoard Appointment
31st Jul 20083:42 pmRNSMajor contract win
21st Jul 20088:45 amRNSNotice of Interim Results
2nd Jul 20088:10 amRNSRe Share Holdings
2nd Jul 20087:03 amRNSDirector's Dealings
1st Jul 20081:08 pmRNSStrategic Partnership
16th Jun 20088:34 amRNSLong Term Incentive Plan
2nd Jun 20089:27 amRNSAGM and Board appointments
2nd Jun 20087:00 amRNSDealings in Shares
20th May 20089:08 amRNSCompletion of aquisition and
9th May 20088:39 amRNSNotice of AGM
7th May 20087:00 amRNSAppointment
6th May 20088:33 amRNSKenya Joint Venture
22nd Apr 200811:19 amRNSInvestor Presentation
7th Apr 20088:37 amRNSAcquisition
1st Apr 20087:01 amRNSFinal Results
31st Mar 20089:19 amRNSNotification re: results
10th Mar 20081:16 pmRNSResults Date
28th Feb 20088:43 amPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.